The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets

Behavioural Brain Research
Manato KotaniKazuhito Ikeda


Antagonism of the dopamine D3 receptor is considered a promising strategy for the treatment of cognitive impairment associated with schizophrenia. We have previously reported that the atypical antipsychotic blonanserin, a dopamine D2/D3 and serotonin 5-HT2A receptor antagonist, highly occupies dopamine D3 receptors at its antipsychotic dose range in rats. In the present study, we evaluated the effects of blonanserin on executive function in common marmosets using the object retrieval with detour (ORD) task. The dopamine D3 receptor-preferring agonist (+)-PD-128907 at 1mg/kg decreased success rate in the difficult trial, but not in the easy trial. Since the difference between the two trials is only cognitive demand, our findings indicate that excess activation of dopamine D3 receptors impairs executive function in common marmosets. Blonanserin at 0.1mg/kg reversed the decrease in success rate induced by (+)-PD-128907 in the difficult trial. This finding indicates that blonanserin has beneficial effect on executive function deficit induced by activation of the dopamine D3 receptor in common marmosets. Next, and based on the glutamatergic hypothesis of schizophrenia, the common marmosets were treated with the N-methyl-d-aspartate ...Continue Reading


Jun 28, 2016·Pharmacology & Therapeutics·Gian Marco LeggioFilippo Drago
Sep 25, 2019·Nature Medicine·Stephan J SandersCarrie E Bearden
Jan 16, 2019·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Takeshi Enomoto, Kazuhito Ikeda


Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Jan 14, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J W NewcomerJ W Olney
Jun 17, 1999·Pharmacology, Biochemistry, and Behavior·A G SmithB Costall
Mar 17, 2000·Brain Research. Brain Research Reviews·P S Goldman-RakicG V Williams
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Herbert Y MeltzerJunji Ichikawa
May 4, 2006·Psychopharmacology·Stan B Floresco, Orsolya Magyar
Dec 25, 2009·CNS Drugs·Emma D Deeks, Gillian M Keating
Apr 23, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Patrick N McCormickAlan A Wilson
Jan 27, 2012·Human Psychopharmacology·Tomomi TenjinNoboru Yamaguchi
Nov 7, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Gerhard GrossKarla U Drescher
Jan 19, 2013·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Patrick N McCormickGary J Remington
Mar 5, 2013·Behavioural Brain Research·Takeshi MuraiKazuhito Ikeda
Jun 25, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Shinichiro NakajimaAriel Graff-Guerrero
Jul 17, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Naomi R DriesenJohn H Krystal
Dec 7, 2013·Behavioural Brain Research·Takeshi MuraiMutsuo Taiji
Aug 15, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hirotake HidaYukihiro Noda
Mar 26, 2015·Behavioural Brain Research·Satoko BabaKazuhito Ikeda
Apr 4, 2015·Journal of Pharmacological Sciences·Satoko BabaMichiko Ono
Dec 18, 2015·Behavioural Brain Research·Manato KotaniKazuhito Ikeda

Related Concepts

Antipsychotic Effect
Atypical Antipsychotic [EPC]
Callithrix jacchus jacchus
Receptor, Serotonin,5-HT2A
Dopamine D3 receptor
Serotonin Measurement

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here